Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CHELATE STUDY: Trientine Tetrahydrochloride (TETA 4HCL) for the Treatment of Wilson's Disease

NCT03539952 is registered in ClinicalTrials.gov with Orphalan as lead sponsor.

NCT NCT03539952
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03539952 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CHELATE STUDY: Trientine Tetrahydrochloride (TETA 4HCL) for the Treatment of Wilson's Disease
Lead sponsor
Orphalan
Phase
Phase 3
Overall status
Completed
Start date
September 3, 2018
Completion date
January 18, 2022
Enrollment
77 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

wilson disease